Rivastigmine Hydrogen Tartrate

Base Information

• Chemical Name: Rivastigmine Hydrogen Tartrate
• CAS No.: 129101-54-8
• Deprecated CAS: 123441-04-3
• Molecular Formula: C18H28N2O8
• Molecular Weight: 400.43
• Hs Code.: 29242990
• European Community (EC) Number: 603-318-3
• UNII: 9IY2357JPE
• Wikidata: Q27133236
• NCI Thesaurus Code: C47707
• RXCUI: 994808
• ChEMBL ID: CHEMBL1201092
• Mol file: 129101-54-8.mol

Synonyms:(S)-N-ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate;713, ENA;713, SDZ ENA;ENA 713;ENA 713, SDZ;ENA-713;ENA713;Exelon;Hydrogen Tartrate, Rivastigmine;rivastigmine;Rivastigmine Hydrogen Tartrate;RivastigmineTartrate;SDZ ENA 713;Tartrate, Rivastigmine Hydrogen

Chemical Property of Rivastigmine Hydrogen Tartrate

Chemical Property:

• Appearance/Colour: white to off-white powder
• Vapor Pressure: 0.000416mmHg at 25°C
• Melting Point: 123-125 ºC
• Boiling Point: 316.2 ºC at 760 mmHg
• Flash Point: 145 ºC
• PSA: 147.84000
• LogP: 0.63710
• Storage Temp.: -20°C Freezer
• Solubility.: H2O: soluble15mg/mL, clear
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 9
• Rotatable Bond Count: 8
• Exact Mass: 400.18456586
• Heavy Atom Count: 28
• Complexity: 402

Purity/Quality:

99% ^*data from raw suppliers

Rivastigmine Tartrate Salt ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C.C(C(C(=O)O)O)(C(=O)O)O
• Isomeric SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
• Recent ClinicalTrials: Treatment of Orthostatic Hypotension in Autonomic Failure
• Recent EU Clinical Trials: Memory, Ageing, and the Cholinergic System
• Indications: Used to treat the symptoms of mild to moderate Alzheimer's disease dementia symptoms.
• Drug Interactions: (1) Rivastigmine is mainly through hydrolysis cholinesterase metabolism, cytochrome P450 isozymes are rarely involved in its metabolism. Therefore, the product and by other drugs metabolized by these enzymes does not exist pharmacokinetic interactions. (2) study in healthy volunteers found the product (a single dose of 3mg) with digoxin, warfarin, diazepam or fluoxetine, have no pharmacokinetic interactions. Warfarin induced by prothrombin time extension are not affected by this product. After combination of digoxin and the product found no adverse impact on cardiac conduction. (3) In clinical studies of patients with Alzheimer's disease (AD), the goods and some commonly used prescription drugs combined, such as antacids, antiemetics, hypoglycemic agents, β-blockers, calcium channel blockers agents, inotropic agents, anti-angina drugs, non-steroidal anti-inflammatory drugs, estrogens, analgesics, tranquilizers, antihistamines, etc., and risk of clinically relevant adverse reaction does not increase (4) In view of the pharmacokinetic effect of this product, this product should not be used in combination with other cholinergic drugs, it may interfere with the activity of anticholinergic drugs. (5) There is no experience of this product with anti Parkinson drugs, anti anxiety drugs (except for stability), antipsychotic drugs, antiepileptic drugs, antidepressant drugs. (6) rivastigmine tartrate as a cholinesterase inhibitor, during anesthesia, it can be used to enhance succinylcholine-type muscle relaxant effect.
• Uses: A brain selective acetylcholinesterase inhibitor. Nootropic. Rivastigmine Tartrate, a cholinesterase inhibitor with IC50 of 5.5 μM, ues as a parasympathomimetic or cholinergic agent for the treatment of mild to moderate Alzheimer disease. Nootropic & Alzheimer’s treatment